LIFECORE BIOMEDICAL, INC. \DE\
جودة البيانات: 83%
LFCR
NASDAQ
Manufacturing
Chemicals
KWD 4.75
▲
KWD 0.03
(0.64%)
القيمة السوقية: 176.89 M
السعر
KWD 4.72
القيمة السوقية
176.89 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Earnings declined -249.51% over the past year
Generating 7.69 M in free cash flow
ROIC of 2.99% — low return on invested capital
Interest coverage of 0.35× — tight debt servicing
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)-249.51%
FCF Growth (3Y)N/A
الجودة
Return on Equity
N/A
ROIC2.99%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio2.80
Interest Coverage0.35
التقييم
PE (TTM|NTM)
-15.09 | -5.72
أقل من متوسط القطاع (-1.49)
P/B RatioN/A
EV/EBITDA18.61
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -15.1 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -54.0 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
3 محللين
Buy
الحالي
KWD 4.75
المستهدف
KWD 6.50
KWD 5.00
KWD 5.50
KWD 9.00
التوقعات
مكرر الربحية المستقبلي
-5.72
ربحية السهم المستقبلية
-KWD 0.87
الإيرادات المقدّرة
131.15 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 0.87
-KWD 0.96 – -KWD 0.78
|
131.15 M | 4 |
| FY2026 |
-KWD 0.89
-KWD 0.93 – -KWD 0.86
|
122.68 M | 4 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.21
-KWD 0.24 – -KWD 0.16
|
29.89 M | 4 |
| 2026 Q1 |
-KWD 0.29
-KWD 0.33 – -KWD 0.24
|
25.96 M | 4 |
مفاجآت الأرباح
آخر 5 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.16 | -KWD 0.16 | 0.0% |
| 2026-Q1 | -KWD 0.29 | -KWD 0.29 | 0.0% |
| Q12025 | -KWD 0.15 | -KWD 0.47 | -213.3% |
| Q42024 | -KWD 0.29 | -KWD 0.25 | +13.8% |
| Q32024 | -KWD 0.49 | -KWD 0.53 | -8.9% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | -249.51% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -11.72 M |
| ROE | N/A | ROA | -4.96% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | 7.69 M |
| ROIC | 2.99% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.80 |
| Interest Coverage | 0.35 | Asset Turnover | N/A |
| Working Capital | 53.97 M | Tangible Book Value | -28.62 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -15.09 | Forward P/E | -5.72 |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 18.61 | Fwd EV/EBITDA | N/A |
| Forward P/S | 1.35 | Fwd Earnings Yield | N/A |
| FCF Yield | 4.35% | ||
| Market Cap | 176.89 M | Enterprise Value | 293.99 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.30 | Revenue / Share | N/A |
| FCF / Share | 0.21 | OCF / Share | 0.26 |
| EPS CAGR (1Y) | -268.75% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -65.64% |
| SBC-Adj. FCF | -3.04 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -17.96 M | 12.01 M | -97.43 M | -99.56 M | -32.67 M |
| EPS (Diluted) | -0.54 | 0.32 | -3.31 | -3.32 | -1.12 |
| Gross Profit | 23.69 M | 41.85 M | 50.37 M | 27.99 M | 81.47 M |
| Operating Income | -733,000.0 | -8.84 M | -41.29 M | -21.80 M | -13.50 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4.97 M | 8.58 M | 7.84 M | 8.74 M | 10.22 M |
| SG&A Expenses | 19.46 M | 40.46 M | 46.13 M | 38.97 M | 65.36 M |
| D&A | 8.03 M | 8.86 M | 17.88 M | 13.29 M | 19.87 M |
| Interest Expense | 15.85 M | — | 17.36 M | 17.65 M | — |
| Income Tax | 337,000.0 | 183,000.0 | -5.84 M | 308,000.0 | -7.80 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 232.18 M | 253.96 M | 295.16 M | 253.55 M | 502.92 M |
| Total Liabilities | 198.12 M | 200.06 M | 187.22 M | 218.46 M | 300.14 M |
| Shareholders' Equity | -14.20 M | 11.32 M | 107.95 M | -4.23 M | 202.78 M |
| Total Debt | 142.24 M | 101.59 M | 98.18 M | 84.84 M | 164.90 M |
| Cash & Equivalents | 17.47 M | 8.46 M | 1.64 M | 19.09 M | 1.30 M |
| Current Assets | 82.29 M | 81.03 M | 123.71 M | 93.88 M | 148.32 M |
| Current Liabilities | 23.57 M | 38.87 M | 79.23 M | 39.29 M | 101.89 M |
{"event":"ticker_viewed","properties":{"ticker":"LFCR","listing_kind":"stock","pathname":"/stocks/lfcr","exchange":"NASDAQ","country":"US"}}
